Fresenius SE & Co KGaA (FRA:FRE) PT Set at €59.40 by JPMorgan Chase & Co.

Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €59.40 ($69.07) price objective by stock analysts at JPMorgan Chase & Co. in a report issued on Tuesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 23.29% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the company. Morgan Stanley set a €50.00 ($58.14) target price on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research note on Monday, September 30th. Deutsche Bank set a €65.00 ($75.58) target price on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research note on Wednesday, October 30th. DZ Bank reaffirmed a “buy” rating on shares of Fresenius SE & Co KGaA in a research note on Monday, November 4th. HSBC set a €53.00 ($61.63) target price on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Finally, Independent Research set a €51.00 ($59.30) target price on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Eight analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of €55.37 ($64.38).

Shares of FRE stock opened at €48.18 ($56.02) on Tuesday. The stock has a 50-day moving average of €49.83 and a 200-day moving average of €46.34. Fresenius SE & Co KGaA has a 1-year low of €60.16 ($69.95) and a 1-year high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

See Also: What is the Coverage Ratio?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.